SCHEMBL23724945

SCHEMBL23724945

Cc1c(Br)cccc1-n1ccc(C=O)cc1=O

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 4/20 0.40
BTK Q06187 4/20 0.40
ALDH1A1 P00352 4/20 0.38
KMT2A Q03164 2/20 0.35
ALDH1A3 P47895 4/20 0.34
P2RX7 Q99572 1/20 0.32
MAPT P10636 2/20 0.31
NPC1 O15118 1/20 0.31
HTT P42858 1/20 0.31
RAB9A P51151 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
LMNA P02545 1/20 0.31
CYP1A2 P05177 1/20 0.31
HPGD P15428 1/20 0.31
CYP2C19 P33261 1/20 0.31
NQO2 P16083 2/20 0.30
KDM4E B2RXH2 1/20 0.30
ALDH3A1 P30838 1/20 0.30
CYP19A1 P11511 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28903500 0.79 JAK2 (0.41) JAK2BTKKMT2AP2RX7MAPT
SCHEMBL23726028 0.76 JAK2 (0.39) JAK2BTKKMT2AP2RX7MAPT
SCHEMBL23725320 0.76 JAK2 (0.39) JAK2BTKKMT2AP2RX7MAPT
SCHEMBL23725318 0.72 MEN1 (0.40) JAK2BTKKMT2A
SCHEMBL23726142 0.72 CD274 (0.46) JAK2BTK
SCHEMBL1753665 0.70 ALDH1A1 (0.41) ALDH1A1KMT2AHTTSMN1; SMN2KDM4E
SCHEMBL13575371 0.70 SMN1; SMN2 (0.56) ALDH1A1KMT2AMAPTHTTSMN1; SMN2
SCHEMBL122227 0.70 BTK (0.46) JAK2BTKALDH1A1KMT2AMAPT
SCHEMBL27609667 0.70 ALDH1A1 (0.38) JAK2BTKALDH1A1KMT2AMAPT
SCHEMBL8107256 0.68 MGLL (0.43) ALDH1A1HTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230143612-A1 SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME ARBUTUS BIOPHARMA CORP (US) 2023-05-11 US disclosed
US-20230143612-A1 SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME ARBUTUS BIOPHARMA CORP (US) 2023-05-11 US disclosed
US-20230143612-A1 SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME ARBUTUS BIOPHARMA CORP (US) 2023-05-11 US disclosed
EP-4100381-A1 SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME Arbutus Biopharma Corporation (CA) 2022-12-14 EP disclosed
CN-115413275-A Substituted 1,1 , -biphenyl compounds and methods of use thereof 爱彼特生物制药公司 2022-11-29 CN disclosed
WO-2021158481-A1 SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME ARBUTUS BIOPHARMA, INC. (US) 2021-08-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230143612-A1 SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME HAVCR2, HMBS, VHL JAK2 1805/4885BTK 1134/4885ALDH1A1 172/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.